Drug Profile
Research programme: cancer therapeutics - Artios Pharma
Alternative Names: DDR - cancer therapeutics - Artios PharmaLatest Information Update: 25 Oct 2021
Price :
$50
*
At a glance
- Originator Cancer Research Technology
- Developer Artios Pharma; Masaryk University
- Class Antineoplastics; Small molecules
- Mechanism of Action DNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer